Send the following on WhatsApp
Continue to Chathttps://de.marketscreener.com/kurs/aktie/INCYTE-CORPORATION-9675/news/Incyte-gibt-positive-Ergebnisse-seiner-Phase-2b-Studie-zu-Ruxolitinib-Creme-bei-Patienten-mit-Neur-27260367/?utm_source=whatsapp&utm_medium=social&utm_campaign=share